Drugs / [203Pb]VMT-α-NET
[203Pb]VMT-α-NET
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05111509 | Aug 2022 → Apr 2026 overdue | carcinoid tumor | Yusuf Menda | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05636618 | Sep 2023 → Nov 2029 expected | bronchial endocrine tumor, digestive system neuroendocrine neoplasm, meningioma, paraganglioma +1 | Perspective Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
All press releases naming this drug 17 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [203Pb]VMT-α-NET | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05111509 ↗ |
| Known as | [203Pb]Pb-VMT-α-NET | “A Phase 0 imaging trial of [203Pb]Pb-VMT-α-NET was conducted between January and December of 2023.” PMID 41644295 ↗ Apr 2026 |
| Known as | PSC-PEG2-TOC | “A promising candidate radiopharmaceutical pair, PSC-PEG2-TOC (VMT-α-NET) conjugated to 203Pb for SPECT/CT imaging or 212Pb for α-PRRT, is currently in early-phase clinical...” PMID 41644295 ↗ Apr 2026 |
| Known as | VMT-α-NET | “A promising candidate radiopharmaceutical pair, PSC-PEG2-TOC (VMT-α-NET) conjugated to 203Pb for SPECT/CT imaging or 212Pb for α-PRRT, is currently in early-phase clinical...” PMID 41644295 ↗ Apr 2026 |
| Modality | Diagnostic / imaging agent | “the imaging agent” NCT05111509 ↗ |
| Route | Intravenous | “administered intravenously” NCT05111509 ↗ |